Inhibrx, Inc. (INBX)
Chart Events
Performance Outlook
| Previous Close | 15.60 |
| Open | 15.60 |
| Bid | 17.69 x 900 |
| Ask | 17.74 x 1200 |
| Day's Range | 15.50 - 18.04 |
| 52 Week Range | 7.67 - 47.90 |
| Volume | |
| Avg. Volume | 481,121 |
| Market Cap | 701.305M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for INBX
Related Research
- Inhibrx, Inc.HRMY: Raising target price to $55.00HARMONY BIOSCIENCES HOLDINGS has an Investment Rating of BUY; a target price of $55.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.RatingFair ValueEconomic Moat8 days agoArgus Research
- PR Newswire
Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance
Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a robust preclinical pipeline, today announced the completion of Phase 1 dose escalation of INBRX-105, a novel targeted 4-1BB agonist, in combination with Keytruda®. It also reported the funding of an additional $60 million from its Loan and Security Agreement, as amended (the "Loan Agreement"), with Oxford Finance, LLC ("Oxford"), to bring its cash balance to approximately $176 million as of Jun
- PR Newswire
Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting
Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that it will be presenting details on the trial design for the INBRX-109 Phase 2 potentially registration-enabling trial in conventional chondrosarcoma at the 2022 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held June 3rd through June 7th, 2022 in Chicago, Illinois.
- Benzinga
Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder
Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. Treatment was well tolerated, with no severe or serious adverse events related to the study drug. Related: Inhibrx Shares Interim Data On INBRX-106 - Keyt
